ERENUMAB
Information current as at: 1 June 2025
The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.
PBAC meeting date: November 2019
Submission Details
- Brand name:
-
- Aimovig®
- Pharmaceutical company:
- Novartis Pharmaceuticals Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Chronic migraine
- PBAC Submission type:
- New listing (Major)
- Comment:
- --
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2019 PBAC meeting
-
Opportunity for consumer comment: - Open 28/08/2019 and close 09/10/2019 (see PBS Website)
-
PBAC meeting: - Not applicable
-
PBAC outcome published: - Not applicable
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a071
Page last updated: 31 July 2024